Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$1.70
-$0.11(-3.01%)
At close: 4:00 PM EST
$1.70
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$1.01 - $7.80
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$159.09M
Enterprise Value$92.00M
Total Cash (Recent Filing)$132.30M
Total Debt (Recent Filing)$16.56M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding69,169,210
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.61
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$9.00Price Target Upside429.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetA low debt-to-equity (~0.12) materially reduces refinancing and interest risks for a development-stage biotech. This conservative leverage profile preserves strategic optionality to fund trials or partner programs without urgent debt pressures, strengthening financial resilience over months.
DM1 Program Clinical ProgressEmerging safety and efficacy signals plus U.S./EU regulatory designations and ongoing global enrollment meaningfully de-risk the lead program over the medium term. Positive clinical readthroughs and designation status increase the probability of partnerships, regulatory paths, and value capture if results persist.
Proprietary EDO Delivery PlatformA differentiated delivery platform that improves oligonucleotide uptake into muscle is a durable competitive asset. Platform applicability across neuromuscular indications supports pipeline expansion, potential licensing opportunities, and sustained R&D leverage independent of a single asset outcome.
Bears Say
No Revenue; Sustained Large LossesAbsence of product revenue and recurring multi‑year losses mean the company must rely on external capital until clinical success. This structural lack of cash inflows limits reinvestment flexibility and leaves long-term viability contingent on trial outcomes or successful partnerships.
High Cash Burn And Weak Cash GenerationConsistently negative operating and free cash flow at material levels creates persistent funding needs. Over a 2–6 month horizon this structural burn increases the likelihood of dilutive financings or constrained program pacing if fundraising windows tighten, impacting strategic execution.
Eroding Equity Base And Dilution RiskA shrinking equity base driven by cumulative losses signals prior dilution or capital use and points to ongoing financing risk. Continued erosion reduces shareholder resilience to further dilutive raises and can limit negotiating leverage for collaborations or non-dilutive funding.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.01 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $159.09M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on May 12, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.033.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.28.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,169,210 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 5.952%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (429.41% Upside)
$9.00 (429.41% Upside)
Hedge Fund Trend
Decreased
By 865.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-59.89%
Trailing 12-Months
Asset Growth
22.69%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$9.00
▲(429.41% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
37.05% Insiders
3.69% Mutual Funds
4.24% Other Institutional Investors
51.24% Public Companies and
Individual Investors